Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma

The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma

The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed ...

Method of synchronizing time between host device and storage device and system performing the same

A method of synchronizing time between a host device and a storage device is provided. The method includes: identifying, by the storage device, a time synchronization interval; notifying the time synchronization interval from the storage device to the host device; providing host time information from the host device to the storage device during the time synchronization interval; and synchronizing, by the storage device, time information of the storage device with the host time information.

METHOD FOR SCREENING ANTICANCER AGENT OR SIP1/ZEB2 INHIBITOR USING INTEGRIN ALPHA 5

The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.

HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Composition Containing Styraxlignolide A or the Aglycone Thereof as an Active Ingredient for Preventing or Treating Asthma

The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of , and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-β1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed. 1. A method for treating asthma , the method comprising administering a pharmaceutical composition containing a pharmaceutically effective amount of styraxlignolide A compound , an aglycone thereof , or a pharmaceutically acceptable salt thereof as an active ingredient to an individual.4Styrax japonica.. The method as set forth in claim 1 , wherein the styraxlignolide A compound is separated from5. The method as set forth in claim 1 , wherein asthma is one in which airway remodeling has progressed.614-. (canceled)15. A method for treating inflammation claim 1 , the method comprising administering a pharmaceutical composition containing a pharmaceutically effective amount of styraxlignolide A compound claim 1 , an aglycone thereof claim 1 , or a pharmaceutically acceptable salt thereof as an active ingredient to an individual.18Styrax japonica.. The method as set forth in claim 15 , wherein the styraxlignolide A compound is separated from 1. Field of the InventionThe present disclosure ...

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT CONTAINING THE C12ORF59 GENE OR PROTEIN AS AN ACTIVE INGREDIENT

As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.

METHOD OF SYNCHRONIZING TIME BETWEEN HOST DEVICE AND STORAGE DEVICE AND SYSTEM PERFORMING THE SAME

A method of synchronizing time between a host device and a storage device is provided. The method includes: identifying, by the storage device, a time synchronization interval; notifying the time synchronization interval from the storage device to the host device; providing host time information from the host device to the storage device during the time synchronization interval; and synchronizing, by the storage device, time information of the storage device with the host time information 1. A system comprising: a storage controller; and', 'a plurality of nonvolatile memory devices; and, 'a storage device comprisinga host device comprising a host processor,wherein the storage controller is configured to identify a time synchronization interval, and control the storage device to notify the time synchronization interval to the host device, andwherein the host processor is configured to control the host device to provide host time information to the storage device during the time synchronization interval.2. The system of claim 1 , wherein the storage controller is further configured to control the storage device to:notify a start of the time synchronization interval to the host device; andnotify an end of the time synchronization interval to the host device.3. The system of claim 2 , wherein the host processor is further configured to control the host device to:provide the host time information to the storage device based on notification of the start of the time synchronization interval; andstop provision of the host time information based on notification of the end of the time synchronization interval.4. The system of claim 1 , wherein the host device and the storage device are configured to communicate with each other according to universal flash storage (UFS) standards.5. The system of claim 4 , wherein the storage controller is further configured to control the storage device to notify the host device of the time synchronization interval using UFS protocol ...

2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient

The present invention relates to a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The 2-hydroxyarylamide derivative prepared by the present invention is excellent in the inhibition of the activity of TMPRSS4 serine protease and the suppression of the infiltration of TMPRSS4-expressed cancer cells, and thus can be useful as a composition for preventing or treating cancer by inhibiting TMPRSS4 over-expressed in cancer cells, particularly, colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, or stomach cancer cells.

Method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5

The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.

PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT CONTAINING PEPTIDE ORIGINATED FROM C12ORF59 PROTEIN AS AN ACTIVE INGREDIENT

As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer. 1. An isolated anti-cancer peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 30 to 39.2. The isolated anti-cancer peptide of claim 1 , wherein the peptide is in the form of a C-terminal amidated peptide claim 1 , a N-terminal acetylated peptide claim 1 , a biotinylated peptide claim 1 , a peptide comprising a non-natural amino acid claim 1 , a peptide comprising protecting group claim 1 , a peptide comprising a chemically-modified amino acid claim 1 , a carboxymethylated peptide claim 1 , a cyclic peptide claim 1 , a dimeric peptide claim 1 , or a peptide conjugated to a carrier.3. The isolated anti-cancer peptide of claim 2 , wherein the carrier is selected from the group consisting of polyethylene glycol (PEG) claim 2 , enzyme claim 2 , immunogloblulin Fc region claim 2 , albumin claim 2 , and keyhole limpet hemocyanin.4. A polynucleotide encoding the peptide of .5. A composition comprising the peptide of .6. A method for treating cancer claim 1 , comprising administering a pharmaceutically effective dose of the isolated anti-cancer peptide of to a subject in need thereof.7. The method of claim 6 , wherein the cancer is selected from the group consisting of ...

Method of treating cancer with a composition containing a C12ORF59 protein

As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

APPARATUS AND METHOD FOR SELECTING A CONTROL OBJECT BY VOICE RECOGNITION

There are provided an apparatus and a method for selecting a control object through voice recognition. The apparatus for selecting a control object through voice recognition according to the present invention includes one or more processing devices, in which the one or more processing devices are configured to obtain input information on the basis of a voice of a user, to match the input information to at least one first identification information obtained based on a control object and second identification information corresponding to the first identification information, to obtain matched identification information matched to the input information within the first identification information and the second identification information, and to select a control object corresponding to the matched identification information. 1. An apparatus for selecting a control object through voice recognition , the apparatus comprising:one or more processing devices,wherein the one or more processing devices are configured to obtain input information on the basis of a voice of a user, to match the input information to at least one first identification information obtained based on a control object and second identification information corresponding to the first identification information, to obtain matched identification information matched to the input information within the first identification information and the second identification information, and to select a control object corresponding to the matched identification information.2. The apparatus for selecting a control object according to claim 1 , wherein the second identification information includes synonym identification information which is a synonym of the first identification information.3. The apparatus for selecting a control object according to claim 1 , wherein the second identification information includes at least one of translation identification information in which the first identification information is ...

Anticancer Drug Comprising Inhibitor of Tmprss4

The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.

APPARATUS AND METHOD FOR GENERATING AN EVENT BY VOICE RECOGNITION

There are provided an apparatus and a method for generating an event through voice recognition. The apparatus for generating an event through voice recognition according to the present invention includes one or more processing devices, in which the one or more processing devices are configured to obtain input information on the basis of a voice of a user, to match the input information to at least one identification information obtained based on application screen information, to obtain matched identification information matched to the input information among the identification information, and to generate an event in at least a partial area of areas corresponding to the matched identification information. 1. An apparatus for generating an event through voice recognition , the apparatus comprising:one or more processing devices,wherein the one or more processing devices are configured to obtain input information on the basis of a voice of a user, to match the input information to at least one identification information obtained based on application screen information, to obtain matched identification information matched to the input information among the identification information, and to generate an event in at least a partial area of areas corresponding to the matched identification information.2. The apparatus for generating an event according to claim 1 , wherein the identification information is obtained through optical character recognition (OCR).3. The apparatus for generating an event according to claim 1 ,wherein the input information includes voice pattern information obtained by analyzing a feature of the voice of the user, andthe matching of the input information to the identification information includes matching of the identification information to the voice pattern information.41. The apparatus for generating an event according to claim claim 1 ,wherein the input information includes text information recognized from the voice of the user through voice ...

ASTHMA DIAGNOSIS USING THE NEUROPILIN-1 GENE, AND METHOD FOR SCREENING FOR A THERAPEUTIC AGENT FOR ASTHMA

The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma. 112-. (canceled)13. A method for the treatment of asthma comprising the step of administering a pharmaceutically effective dose of NRP1 (Neuropilin-1) gene expression or activity inhibitor to a subject with asthma.14. The method for the treatment of asthma according to claim 13 , wherein NRP1 expression or activity inhibitor is selected from the group consisting of antisense nucleotide binding complementarily to NRP1 mRNA claim 13 , short interfering RNA claim 13 , short hairpin RNA claim 13 , and antibody binding complementarily to NRP1 protein.1516-. (canceled)17. The method for the treatment of asthma according to claim 13 , wherein the NRP1 gene has the nucleotide sequence of SEQ. ID. NO: 1.18. A method for the treatment of asthma comprising the step of administering a pharmaceutically effective dose of NRP1 (Neuropilin-1) short interfering RNA to a subject with asthma.19. A method for the treatment of asthma comprising the step of administering a pharmaceutically effective dose of NRP1 (Neuropilin-1) antibody to a subject with asthma. 1. Field of the InventionThe present invention relates to a use of NRP1 gene as a target for the development of an asthma marker or a therapeutic agent for asthma.2. Description of the Related ArtAnaphylaxis, allergic rhinitis, asthma, atopic dermatitis, and urticaria are the examples of allergic diseases whose incidence ...

APPARATUS AND METHOD FOR SELECTING CONTROL OBJECT THROUGH VOICE RECOGNITION

There are provided an apparatus and a method for selecting a control object through voice recognition. The apparatus for selecting a control object according to the present invention that is an apparatus for selecting a control object through voice recognition includes one or more processing devices, in which the one or more processing devices are configured to obtain input information on the basis of a voice of a user, to match the input information to at least one identification information obtained based on a control object, to obtain matched identification information matched to the input information among the identification information, and to select a control object corresponding to the matched identification information. 1. An apparatus for selecting a control object through voice recognition , the apparatus comprising:one or more processing devices,wherein the one or more processing devices are configured to obtain input information on the basis of a voice of a user, to match the input information to at least one identification information obtained based on a control object, to obtain matched identification information matched to the input information among the identification information, and to select a control object corresponding to the matched identification information.2. The apparatus for selecting a control object according to claim 1 , wherein the identification information is obtained based on display information about the control object.3. The apparatus for selecting a control object according to claim 2 , wherein the identification information is obtained based on application screen information.4. The apparatus for selecting a control object according to claim 2 , wherein the identification information is obtained through optical character recognition (OCR).5. The apparatus for selecting a control object according to claim 1 ,wherein the input information includes voice pattern information obtained by analyzing a feature of the voice of the user, ...

2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient

The present invention relates to a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The 2-hydroxyarylamide derivative prepared by the present invention is excellent in the inhibition of the activity of TMPRSS4 serine protease and the suppression of the infiltration of TMPRSS4-expressed cancer cells, and thus can be useful as a composition for preventing or treating cancer by inhibiting TMPRSS4 over-expressed in cancer cells, particularly, colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, or stomach cancer cells.

HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. 1. A single chain variable fragment (ScFv) molecule comprising:a light chain variable region comprising the amino acid sequence of any one of SEQ ID NOS: 2 to 6, 10 and 11, anda heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20,wherein the ScFv molecule functions to neutralize vascular endothelial growth factor receptor.2. A composition for inhibiting angiogenesis comprising the ScFv molecule of .3. A composition for treating cancer comprising the ScFv molecule of .4. An IgG antibody comprising:a light chain variable region comprising the an amino acid sequence of any one of SEQ ID NOS: 2 to 6, 10 and 11, anda heavy chain variable region comprising the an amino acid sequence of SEQ ID NO: 20,wherein the antibody functions to neutralize vascular endothelial growth factor receptor.5. A composition for inhibiting angiogenesis comprising the IgG antibody of .6. A composition for treating cancer comprising the IgG antibody of . This application is a divisional application of U.S. patent application Ser. No. 12/664,226, filed on Nov. 19, 2010 (currently pending), the disclosure of which is ...

HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. 1. A single chain variable fragment (ScFv) molecule comprising:a light chain variable region comprising the amino acid sequence of any one of SEQ ID NOS: 12 and 16 to 20, anda heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20,wherein the ScFv molecule functions to neutralize vascular endothelial growth factor receptor.2. A composition for inhibiting angiogenesis comprising the ScFv molecule of .3. A composition for treating cancer comprising the ScFv molecule of .4. An IgG antibody comprising:a light chain variable region comprising the an amino acid sequence of any one of SEQ ID NOS: 12 and 16 to 20, anda heavy chain variable region comprising the an amino acid sequence of SEQ ID NO: 20,wherein the antibody functions to neutralize vascular endothelial growth factor receptor.5. A composition for inhibiting angiogenesis comprising the IgG antibody of .6. A composition for treating cancer comprising the IgG antibody of . This application is a divisional application of U.S. patent application Ser. No. 12/664,226, filed on Nov. 19, 2010 (currently pending), the disclosure of which is ...

An anticancer drug comprising inhibitor of tmprss4

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives

The present invention relates to novel compounds having ([1,3]thiazolo[5,4- b]pyridine-2-yl)-2-carboxamide structure, as being illustrated in Formula 1, for inhibition of angiogenesis receptor tyrosine kinases, in particular, VEGF receptor 2 kinase ('KDR') activity, methods for preparing the same, their use and a pharmaceutical composition comprising thereapeutically effective amount of the said compounds. The compounds according to the present invention are useful for the treatment and prevention of angiogenesis-related diseases, particularly resulting from the unregulated or undesired KDR activity, such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc.

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Storage device and operating method thereof

A storage device and an operating method thereof are provided. The storage device includes a non-volatile memory, an interconnect, a device controller and a buffer memory. The interconnect exchanges data with a host, receives a logging target setting request and a logging period setting request with respect to debugging information from the host, receives a debugging information logging request from the host, and receive a read request from the host. The device controller includes a buffer memory and controls the non-volatile memory, controls a logging operation on the debugging information based on a logging target and a logging period, which are requested by the host, in response to the debugging information logging request, and transmits the debugging information to the host in response to the read request. The device controller is further configured to logs the debugging information in the buffer memory according to the debugging information logging request.

Verfahren zum Synchronisieren einer Zeit zwischen einer Hostvorrichtung und einer Speichervorrichtung und System zum Durchführen desselben

Es wird ein Verfahren zum Synchronisieren einer Zeit zwischen einer Hostvorrichtung und einer Speichervorrichtung bereitgestellt. Das Verfahren beinhaltet folgende Schritte: Identifizieren, durch die Speichervorrichtung, eines Zeitsynchronisierungsintervalls; Melden des Zeitsynchronisierungsintervalls von der Speichervorrichtung zur Hostvorrichtung; Bereitstellen von Hostzeitinformationen von der Hostvorrichtung zur Speichervorrichtung während des Zeitsynchronisierungsintervalls; und Synchronisieren, durch die Speichervorrichtung, von Zeitinformationen der Speichervorrichtung mit den Hostzeitinformationen.

ホスト装置とストレージ装置間の時間同期化方法及びそのシステム

【課題】ホスト装置とストレージ装置の間の効率的な時間同期化方法及びそれを行うシステムを提供する。【解決手段】本発明による時間同期化方法は、ホスト装置とストレージ装置との間の時間同期化方法であって、前記ストレージ装置において、前記ホスト装置の時間情報が必要な時間同期化区間を決定するステップと、前記ストレージ装置から前記ホスト装置に、前記時間同期化区間を通知するステップと、前記時間同期化区間の間に、前記ホスト装置から前記ストレージ装置に、前記ホスト装置の時間情報を提供するステップと、前記ストレージ装置において、前記ホスト装置の時間情報に基づいて、前記ストレージ装置の時間情報を前記ホスト装置の時間情報に同期化するステップと、を有する。【選択図】 図１

Pharmaceutical composition for cancer prevention and treatment containing peptide originated from C12orf59 protein as an active ingredient

As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.